AU2012335409B2 - 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use - Google Patents

5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use Download PDF

Info

Publication number
AU2012335409B2
AU2012335409B2 AU2012335409A AU2012335409A AU2012335409B2 AU 2012335409 B2 AU2012335409 B2 AU 2012335409B2 AU 2012335409 A AU2012335409 A AU 2012335409A AU 2012335409 A AU2012335409 A AU 2012335409A AU 2012335409 B2 AU2012335409 B2 AU 2012335409B2
Authority
AU
Australia
Prior art keywords
papc
cancer
compound
compound according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012335409A
Other languages
English (en)
Other versions
AU2012335409A1 (en
Inventor
Ian Collins
Michael LAINCHBURY
Thomas Peter Matthews
John Charles Reader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2012335409A1 publication Critical patent/AU2012335409A1/en
Application granted granted Critical
Publication of AU2012335409B2 publication Critical patent/AU2012335409B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012335409A 2011-11-09 2012-11-09 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use Ceased AU2012335409B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557457P 2011-11-09 2011-11-09
US61/557,457 2011-11-09
PCT/GB2012/052786 WO2013068755A1 (en) 2011-11-09 2012-11-09 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use

Publications (2)

Publication Number Publication Date
AU2012335409A1 AU2012335409A1 (en) 2014-04-17
AU2012335409B2 true AU2012335409B2 (en) 2017-07-13

Family

ID=47178213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012335409A Ceased AU2012335409B2 (en) 2011-11-09 2012-11-09 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use

Country Status (10)

Country Link
US (3) US9040540B2 (enExample)
EP (1) EP2776417B1 (enExample)
JP (1) JP6073910B2 (enExample)
CN (1) CN104105696B (enExample)
AU (1) AU2012335409B2 (enExample)
BR (1) BR112014010938A2 (enExample)
CA (1) CA2849566C (enExample)
ES (1) ES2709003T3 (enExample)
RU (1) RU2641693C2 (enExample)
WO (1) WO2013068755A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
CZ306322B6 (cs) 2014-12-17 2016-11-30 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN110872277B (zh) * 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044162A1 (en) * 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
WO2009103966A1 (en) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
DE60221866T2 (de) 2001-10-19 2008-05-29 Ortho-Mcneil Pharmaceutical, Inc. 2-PHENYL BENZIMIDAZOLE UND IMIDAZO-i4,5ö-PYRIDINE ALS CDS1/CHK2-INHIBITOREN UND ADJUVANTIEN IN DER CHEMOTHERAPIE ODER STRAHLUNGSTHERAPIE ZUR BEHANDLUNG VON KREBS
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2003037898A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
CN1860118A (zh) 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EP1673343A4 (en) 2003-10-08 2008-09-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
ATE458730T1 (de) 2004-04-13 2010-03-15 Icagen Inc Polycyclische pyrazine als kaliumionenkanal- modulatoren
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101189239A (zh) 2005-04-28 2008-05-28 休普基因公司 蛋白激酶抑制剂
ES2331853T3 (es) 2005-06-28 2010-01-18 Sanofi-Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
ATE533770T1 (de) 2005-10-06 2011-12-15 Schering Corp Pyrazolopyrimidine als proteinkinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US8501765B2 (en) * 2008-06-11 2013-08-06 Genentech, Inc. Diazacarbazoles and methods of use
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044162A1 (en) * 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
WO2009103966A1 (en) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use

Also Published As

Publication number Publication date
AU2012335409A1 (en) 2014-04-17
US20160304493A1 (en) 2016-10-20
CN104105696B (zh) 2017-11-14
US20150225372A1 (en) 2015-08-13
CN104105696A (zh) 2014-10-15
US20140315925A1 (en) 2014-10-23
CA2849566C (en) 2021-02-09
RU2014121334A (ru) 2015-12-20
EP2776417B1 (en) 2018-10-31
EP2776417A1 (en) 2014-09-17
US9040540B2 (en) 2015-05-26
CA2849566A1 (en) 2013-05-16
JP6073910B2 (ja) 2017-02-01
JP2014532751A (ja) 2014-12-08
US9765059B2 (en) 2017-09-19
BR112014010938A2 (pt) 2017-05-16
RU2641693C2 (ru) 2018-01-22
WO2013068755A1 (en) 2013-05-16
ES2709003T3 (es) 2019-04-12
US9403797B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
AU2017268508B2 (en) 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
US9765059B2 (en) 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
WO2010007389A1 (en) 5 -amidothiazole derivatives and their use as checkpoint kinase inhibitors
HK1243408B (en) Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired